Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.08 | Change: +$0.05 | %Change: +0.99%
Volume: 24,497 | Day High/Low: 5.17/4.97 | 52 Week High/Low: 10.36/2.50
View modes: 
1 star

Its Coming

Its been rumored that Nuvo will be gone late this year. It might be sooner. Waiting later will be more costly, what with those record sales of P2 and WF10 successfully through its trials. With Bloom...read more
0 stars

Earnings per share

So how is it that a stock that has earnings of  $3.85 a share with huge growth on the horizon  at $5.00?  rate and reply
0 stars

RE:RE:RE:Remarkable sales

Exactly. Such sales will also generate about $20 million or more in annual production sales. Along with $5 million in product sales outside US, we have about $25 million in currrent annual product...read more
0 stars

Valeant To Expand Further in Canada

lobe says Valeant to expand further in Canada 2015-05-22 07:48 ET - In the News   The Globe and Mail reports in its Friday edition Valeant Pharmaceuticals ($285.23) plans to expand its presence...read more
0 stars

RE:RE:RE:RE:New presentation today and new Pennsaid 2% numbers

Horizon will have two more presentations during June as of their news release yesterday. 2015-05-21 10:45 ET - News Release   DUBLIN, IRELAND -- (Marketwired) -- 05/21/15 Horizon Pharma plc...read more
0 stars

Exerpts From Bloom Burton Interview

DM: I cover three specialty pharma companies— Knight Therapeutics Inc. (GUD:TSX; KHTRF:OTCMKTS), Concordia Healthcare Corp. (CXR:TSX) and Tribute Pharmaceuticals Canada Inc. (TRX:TSX.V; TBUFF:OTCQX...read more
0 stars

RE:RE:Remarkable sales

2j3k, That is my thinking exactly. Overtaking Voltaren in the US, which has been in ubiquitous use by consumers for the last few years, clearly shows that Europe sales of P2 can secure profits for...read more
5 stars

RE:Directional Assist

No idea wtf you’re talking about, but a "bow thruster" sounds like something I'd like to stick up management's a$$!  rate and reply
0 stars

Directional Assist

A small bow thruster has been added. If it is inadequate, a larger one  can be called upon..  rate and reply
5 stars

RE:RE:Remarkable sales

The complaint is we are dealing with a non- normal group on this MGT team. Anyone that has used Pennsaid over the years knew all along that it was a game changer. Bet you no one on the BOD used it...read more
5 stars

Remarkable sales

As a current Voltaren user, slobbering the stuff on my knees, I am really excited at the rapid sales growth shown by P2 in the US. And I still believe that unless the previous trial a few years ago...read more
0 stars

RE:Remarkable sales

I think we need point out that management own 1.2 million shares plus options. I dont recall any insider  selling when the stock ran up to $10 in January. Some of us did. Were they too dumb ? Did...read more
0 stars

WF10 Inflamax Study Brochure?

I assume this is the WF10 study brocuhure found at the Inflamax site.  You could make $500 referring a test subject or $4,200 being a subject! http://www.sneezetoronto.com/wp-content/uploads/2015/05...read more
0 stars

RE:RE:RE:New presentation today and new Pennsaid 2% numbers

Praying for that day.  rate and reply
0 stars

RE:RE:New presentation today and new Pennsaid 2% numbers

I heard the bigger than Tylenol bit from a dr who used it for a tat...no pain. I overheard a lot of stuff back in the day...hmm. Tthis wild pie in the sky optimism re possibility and potential is...read more
5 stars

RE:New presentation today and new Pennsaid 2% numbers

Script growth is now accelerating, as branding starts to amplify detailing sales efforts. The runrate is now about $180 million US per year which matches Voltaren Gel. This is a remarkable...read more
0 stars

Marketing Rights Israel,Latin America plus S Africa

Nuvo owns all ex U.S. Pennsaid 2 per cent rights in South and Central America as well as Israel and South Africa. These are all strong OTC markets where  FDA approval might be sufficient. As the...read more
0 stars

$200 million runlet by mid-June

The magic number is 7000 scripts per week. If one assumes 250 script gains per week, that is. Recent gains have been more than that. $200 million will provide over  $20 million in manufacturing sales...read more
0 stars

Why I'm staying long at 4.87, stop at 4.40

So, let me say that I have the greatest sympathy for long time investors.  Those who invested at $30, 6 years ago.  That hurts.  I have been there (not with this stock but many others when I was more...read more
0 stars

RE:New presentation today and new Pennsaid 2% numbers

Too bad most investors will never see a profit.  rate and reply